Journal
JOURNAL OF NUCLEAR MEDICINE
Volume 59, Issue 3, Pages 469-478Publisher
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.117.198119
Keywords
PROMISE; miTNM; PSMA-ligand PET/CT; standardized evaluation; interpretation; criteria
Funding
- Deutsche Forschungsgemeinschaft [807122, Sonderforschungsbereich 824]
- Fondation ARC pour la recherche sur le cancer [SAE20160604150]
Ask authors/readers for more resources
Prostate-specific membrane antigen (PSMA)-ligand PET imaging provides unprecedented accuracy for whole-body staging of prostate cancer. As PSMA-ligand PET/CT is increasingly adopted in clinical trials and routine practice worldwide, a unified language for image reporting is urgently needed. We propose a molecular imaging TNM system (miTNM, version 1.0) as a standardized reporting framework for PSMA-ligand PET/CT or PET/MRI. miTNM is designed to organize findings in comprehensible categories to promote the exchange of information among physicians and institutions. Additionally, flowcharts integrating findings of PSMA-ligand PET and morphologic imaging have been designed to guide image interpretation. Specific applications, such as assessment of prognosis or impact on management, should be evaluated in future trials. miTNM is a living framework that evolves with clinical experience and scientific data.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available